201 related articles for article (PubMed ID: 32986682)
1. The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
Huang X; Lewis MM; Van Scoy LJ; De Jesus S; Eslinger PJ; Arnold AC; Miller AJ; Fernandez-Mendoza J; Snyder B; Harrington W; Kong L; Wang X; Sun D; Delnomdedieu M; Duvvuri S; Mahoney SE; Gray DL; Mailman RB
J Parkinsons Dis; 2020; 10(4):1515-1527. PubMed ID: 32986682
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
Papapetropoulos S; Liu W; Duvvuri S; Thayer K; Gray DL
Neurodegener Dis; 2018; 18(5-6):262-269. PubMed ID: 30453303
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Dopamine D1 Receptor Partial Agonist, PF-06669571, in Subjects with Idiopathic Parkinson's Disease.
Gurrell R; Duvvuri S; Sun P; DeMartinis N
Clin Drug Investig; 2018 Jun; 38(6):509-517. PubMed ID: 29478239
[TBL] [Abstract][Full Text] [Related]
4. A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity.
Balice-Gordon R; Honey GD; Chatham C; Arce E; Duvvuri S; Naylor MG; Liu W; Xie Z; DeMartinis N; Harel BT; Braley GH; Kozak R; Park L; Gray DL
Int J Neuropsychopharmacol; 2020 May; 23(5):287-299. PubMed ID: 32055822
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D
Lewis MM; Van Scoy LJ; De Jesus S; Hakun JG; Eslinger PJ; Fernandez-Mendoza J; Kong L; Yang Y; Snyder BL; Loktionova N; Duvvuri S; Gray DL; Huang X; Mailman RB
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238699
[TBL] [Abstract][Full Text] [Related]
6. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ; Aldred J; Budur K; Fisseha N; Fung VS; Jeong A; Kimber TE; Klos K; Litvan I; O'Neill D; Robieson WZ; Spindler MA; Standaert DG; Talapala S; Vaou EO; Zheng H; Facheris MF; Hauser RA
Lancet Neurol; 2022 Dec; 21(12):1099-1109. PubMed ID: 36402160
[TBL] [Abstract][Full Text] [Related]
8. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
Olanow CW; Kieburtz K; Odin P; Espay AJ; Standaert DG; Fernandez HH; Vanagunas A; Othman AA; Widnell KL; Robieson WZ; Pritchett Y; Chatamra K; Benesh J; Lenz RA; Antonini A;
Lancet Neurol; 2014 Feb; 13(2):141-9. PubMed ID: 24361112
[TBL] [Abstract][Full Text] [Related]
9. Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
Politis M; Sauerbier A; Loane C; Pavese N; Martin A; Corcoran B; Brooks DJ; Ray-Chaudhuri K; Piccini P
Mov Disord; 2017 Feb; 32(2):235-240. PubMed ID: 27859651
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia.
Arce E; Balice-Gordon R; Duvvuri S; Naylor M; Xie Z; Harel B; Kozak R; Gray DL; DeMartinis N
J Psychopharmacol; 2019 Oct; 33(10):1237-1247. PubMed ID: 31264510
[TBL] [Abstract][Full Text] [Related]
11. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
Olanow CW; Espay AJ; Stocchi F; Ellenbogen AL; Leinonen M; Adar L; Case RJ; Orenbach SF; Yardeni T; Oren S; Poewe W;
J Parkinsons Dis; 2021; 11(1):177-186. PubMed ID: 33164945
[TBL] [Abstract][Full Text] [Related]
12. Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®).
Hauser RA; Zeitlin L; Fisher S; D'Souza R
Parkinsonism Relat Disord; 2021 Jan; 82():133-137. PubMed ID: 33360173
[TBL] [Abstract][Full Text] [Related]
13. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
14. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
LeWitt PA; Verhagen Metman L; Rubens R; Khanna S; Kell S; Gupta S
Clin Neuropharmacol; 2018; 41(2):47-55. PubMed ID: 29432286
[TBL] [Abstract][Full Text] [Related]
15. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
[TBL] [Abstract][Full Text] [Related]
17. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
18. Levodopa/carbidopa intestinal gel infusion can improve camptocormia in Parkinson's disease.
Morales-Briceño H; Mahant N; Duma S; Martin A; Griffith J; Tsui D; Fung VS
Parkinsonism Relat Disord; 2019 Aug; 65():282-283. PubMed ID: 31221564
[No Abstract] [Full Text] [Related]
19. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
Markham A; Benfield P
CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
[TBL] [Abstract][Full Text] [Related]
20. A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease.
Farbman ES; Waters CH; LeWitt PA; Rudzińska M; Klingler M; Lee A; Qian J; Oh C; Hauser RA
Parkinsonism Relat Disord; 2020 Dec; 81():144-150. PubMed ID: 33130477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
